Track: Genomics and Cancer Biomarkers

Genomics and biomarkers have transformed the landscape of cancer research and treatment. By identifying DNA mutations, gene expression patterns, and molecular targets, clinicians can develop personalized therapy plans that significantly improve survival rates and treatment effectiveness. This session delves into the latest advances in genomic sequencing, biomarker validation, and translational research that connects laboratory discoveries to clinical applications. The discussion emphasizes the growing importance of predictive and prognostic biomarkers that help determine treatment resistance, disease progression, and patient response. Attendees will gain a comprehensive understanding of how genomics is revolutionizing cancer care.

Predictive Biomarkers - Predictive biomarkers help determine which patients will benefit from a particular treatment or targeted therapy. These markers play a key role in personalized medicine by identifying drug responsiveness, therapy resistance, or immune sensitivity. They enable clinicians to avoid ineffective treatments and select optimal therapeutic approaches.

Prognostic Biomarkers - Prognostic biomarkers provide insights into disease severity, recurrence risk, and overall patient outcomes. They help doctors predict tumor progression and survival rates independent of treatment. This information guides timely decision-making and risk classification, allowing for better monitoring and follow-up strategies.

Genetic Mutations - Genetic mutations influence tumor growth and treatment response. Mutations like BRCA1/2 guide breast cancer therapy choices, while EGFR and KRAS mutations are crucial in lung and colon cancers. Understanding these mutations allows clinicians to select targeted drugs that block specific cancer-driving pathways.

Liquid Biopsy Biomarkers - Liquid biopsies detect circulating tumor DNA, tumor cells, or exosomes in blood. They offer a non-invasive method for real-time monitoring of treatment response, recurrence risk, and mutation development. Liquid biopsies are revolutionizing early detection and enabling dynamic cancer management.

Epigenetic Biomarkers - Epigenetic markers—such as DNA methylation and histone modification—provide insights into tumor initiation and progression. These biomarkers are valuable for early cancer detection and risk assessment. They also guide research into therapies that reverse harmful epigenetic changes.

4th International Conference on Cancer and Breast Cancer Treatment

Track: Genomics and Cancer Biomarkers

Scientific Highlights

Organization Location

Mail us at

Our Social Presence

Call us at